Machine Learning

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A Japanese EdTech firm is offering unlimited free English lessons in Brazil. Is this a savvy market capture or a high-risk gamble in a crowded space?

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

Paychex is betting on AI to transform HR, from automating payroll to mining unstructured data. Is this the future of workforce management?

A new point-of-care PCR test is moving closer to reality in India, promising to revolutionize the fight against tuberculosis and cervical cancer.

Nokia is doubling down on open networking with SONiC, a strategic move to challenge proprietary giants and carve out a crucial role in AI infrastructure.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

Nova Era Labs promises to revolutionize AI education with virtual labs. But in a market of giants, can it deliver on its bold claims of workforce readiness?

A new flooring finish promises unprecedented durability and safety, transforming high-traffic commercial spaces from clinics to retail boutiques.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

As the humanoid robotics market soars towards $7.7B, one firm is recruiting top talent to find the next big winner. What does this move signal to investors?

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

FBI data shows most active threats begin outdoors. New tech is extending security beyond the building, creating an integrated, automated defense.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

With advanced ZK tech and a key exchange partnership, Mantle is positioning itself as the institutional-grade bridge between Wall Street and tokenized assets.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.